198 related articles for article (PubMed ID: 38471722)
1. Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice.
Xie T; Rui H; Liu H; Liu X; Liu X; Li P
Lupus Sci Med; 2024 Mar; 11(1):. PubMed ID: 38471722
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
Zhang X; Wang G; Bi Y; Jiang Z; Wang X
Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
[TBL] [Abstract][Full Text] [Related]
3. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid prevents CD138 expression in T cells of autoimmune MRL/
Xie T; Liu H; Li P
Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35514318
[TBL] [Abstract][Full Text] [Related]
5. CD138 promotes the accumulation and activation of autoreactive T cells in autoimmune MRL/lpr mice.
Xie T; Liu X; Li P
Exp Ther Med; 2023 Dec; 26(6):568. PubMed ID: 37954119
[TBL] [Abstract][Full Text] [Related]
6. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
[TBL] [Abstract][Full Text] [Related]
7. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
[TBL] [Abstract][Full Text] [Related]
8. Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.
Liu L; Takeda K; Akkoyunlu M
Front Immunol; 2020; 11():1569. PubMed ID: 32849532
[TBL] [Abstract][Full Text] [Related]
9. LangChuangHeJi decoction ameliorates lupus via preventing accumulation of CD138+ T cells in MRL/lpr mice.
Xie T; Liu X; Liu H; Han X; Zhao J; Zhou D; Wang Y; Zhang H; Wang P; Li P
Am J Transl Res; 2021; 13(11):12440-12460. PubMed ID: 34956465
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
12. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
[TBL] [Abstract][Full Text] [Related]
13. Characterization of reciprocal Lmb1-4 interval MRL-Faslpr and C57BL/6-Faslpr congenic mice reveals significant effects from Lmb3.
Santiago-Raber ML; Haraldsson MK; Theofilopoulos AN; Kono DH
J Immunol; 2007 Jun; 178(12):8195-202. PubMed ID: 17548658
[TBL] [Abstract][Full Text] [Related]
14. Systemic blockade of proBDNF inhibited the expansion and altered the transcriptomic expression in CD3
Zha AH; Luo C; Shen WY; Fu D; Dai RP
Lupus Sci Med; 2022 Dec; 9(1):. PubMed ID: 36581381
[TBL] [Abstract][Full Text] [Related]
15. CD4(+)B220(+)TCRγδ(+) T cells produce IL-17 in lupus-prone MRL/lpr mice.
Qiu F; Li T; Zhang K; Wan J; Qi X
Int Immunopharmacol; 2016 Sep; 38():31-9. PubMed ID: 27235595
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
18. EGR2 is elevated and positively regulates inflammatory IFNγ production in lupus CD4
Dai R; Heid B; Xu X; Xie H; Reilly CM; Ahmed SA
BMC Immunol; 2020 Jul; 21(1):41. PubMed ID: 32646370
[TBL] [Abstract][Full Text] [Related]
19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
20. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.
Yasuda K; Watkins AA; Kochar GS; Wilson GE; Laskow B; Richez C; Bonegio RG; Rifkin IR
PLoS One; 2014; 9(7):e103478. PubMed ID: 25076492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
